Stryker Co. (NYSE:SYK) Shares Purchased by First Business Financial Services Inc.

First Business Financial Services Inc. increased its position in shares of Stryker Co. (NYSE:SYK) by 3.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 8,905 shares of the medical technology company’s stock after acquiring an additional 278 shares during the quarter. Stryker makes up approximately 0.3% of First Business Financial Services Inc.’s holdings, making the stock its 29th biggest holding. First Business Financial Services Inc.’s holdings in Stryker were worth $3,206,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Kohmann Bosshard Financial Services LLC acquired a new stake in Stryker during the fourth quarter worth approximately $25,000. Dunhill Financial LLC boosted its position in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares during the last quarter. Centricity Wealth Management LLC acquired a new stake in Stryker during the fourth quarter worth approximately $30,000. BankPlus Trust Department acquired a new stake in Stryker during the fourth quarter worth approximately $33,000. Finally, Darwin Wealth Management LLC acquired a new stake in Stryker during the third quarter worth approximately $36,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

SYK stock opened at $396.10 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The firm has a market cap of $151.14 billion, a P/E ratio of 51.04, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. The stock has a 50-day simple moving average of $381.96 and a 200-day simple moving average of $372.45.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the firm posted $3.46 earnings per share. On average, equities analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.85%. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Analysts Set New Price Targets

SYK has been the topic of a number of analyst reports. Truist Financial raised their target price on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research report on Thursday, January 30th. Royal Bank of Canada lifted their price target on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Argus set a $450.00 price target on shares of Stryker in a report on Monday, February 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 price target on shares of Stryker in a report on Wednesday, January 29th. Finally, JMP Securities reiterated a “market perform” rating on shares of Stryker in a report on Tuesday, February 18th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $422.15.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.